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Abstract
Electrochemotherapy is a combined use of certain chemotherapeutic drugs and electric pulses applied to the treated tumour nodule. Local
application of electric pulses to the tumour increases drug delivery into cells, specifically at the site of electric pulse application. Drug uptake by
delivery of electric pulses is increased for only those chemotherapeutic drugs whose transport through the plasma membrane is impeded. Among
many drugs that have been tested so far, bleomycin and cisplatin found their way from preclinical testing to clinical use. Clinical data collected within
a number of clinical studies indicate that approximately 80% of the treated cutaneous and subcutaneous tumour nodules of different malignancies
are in an objective response, from these, approximately 70% in complete response after a single application of electrochemotherapy. Usually only
one treatment is needed, however, electrochemotherapy can be repeated several times every few weeks with equal effectiveness each time. The
treatment results in an effective eradication of the treated nodules, with a good cosmetic effect without tissue scarring.
Protocol
The treatment procedure for electrochemotherapy consists of local or systemic drug injection followed by delivery of electric pulses applied to the
tumour 1. Detailed information about the treatment is published in Standard Operating Procedures (SOP) 2.
Treatment indications:
Treatment procedure:
Other features of the treatment:
Due to lack of systemic toxicity - because very low doses of bleomycin or cisplatin are needed - patients can be treated on an out-patient basis,
and can leave the hospital soon after the treatment.
Discussion
Increase in cytotoxicity of bleomycin by exposure of cells to electroporative electric pulses was first described by Okino M and Mir LM 3,4. Thereafter
electrochemotherapy was demonstrated to be effective also for cisplatin 5. Extensive preclinical data were collected on in vitro and in vivo tumour
models in the following years. Treatment effectiveness was determined in relation to drug dosage, route of its administration, timing of drug injection
and application of electric pulses, intensity of the electric field, coverage with sufficiently high electric field (E), and appropriate selection of
electrodes and positioning with respect to the tumour 1,6,7,8. Furthermore, mechanisms underlying the effectiveness of electrochemotherapy were
elaborated, demonstrating that, besides direct effect of electrochemotherapy to tumour cells, vascular disrupting effect and immune response are
involved 1,6,9. All of these collected data enabled translation of electrochemotherapy into the clinics.
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1. Tumour type: basal cell carcinoma, and cutaneous metastases of malignant melanoma, breast carcinoma, hypernephroma, Kaposi's sarcoma
and others.
2. Tumour location: accessible cutaneous and subcutaneous tumour nodules on all parts of the body.
3. Tumour size can be from 3 mm to 3-5 cm in diameter.
4. Number of nodules; from 1 to up to 100.
1. Local or general anaesthesia, depending on the number of the treated nodules and the location.
2. Drug choice: cisplatin or bleomycin. Cisplatin and bleomycin can be injected intratumorally, bleomycin also intravenously in a dose of 15000
IU/m2. Injected dose for intratumoural application of bleomycin is 250-1000 IU/cm3 of tumour tissue and for cisplatin 0.5 -1 mg/cm3 of tumour
tissue
3. Time interval between the drug administration and application of electric pulses; after intratumoral injection of the drug immediately, after
intravenous administration after 8 min. up to 28 min.
4. Electric pulse generator for electrochemotherapy should provide square wave electric pulses of amplitude 1000 V or more, repetition
frequency from 1 Hz to 5 kHz.
5. Electric pulse parameters: 8 pulses of e.g. 1000 V at 8 mm distance between two plate electrodes, frequency 1 Hz or 5 kHz, duration of the
pulse 100 µs.
6. If the whole tumour can not be encompassed between the electrodes, application of electric pulses should be repeated that many times so as
to cover the whole tumour area, including safety margins.
7. Electrode type: plate electrodes are used for small, superficial tumour nodules, needle electrodes are for treatment of deeper seeded nodules
under the skin.
1. Usually single treatment is effective for tumour nodule eradication; however electrochemotherapy can be repeated in 4 weeks intervals on the
remaining tumour tissue or other tumour nodules.The first clinical trials demonstrated effectiveness of electrochemotherapy on head and neck and melanoma tumour nodules 10. Later on, its
effectiveness was demonstrated on other tumour types, such as basal cell carcinoma of the skin, cutaneous metastases of melanoma, mammary
tumours, hypernephroma and Kaposi's sarcoma. There are several reports evaluating collectively all clinical data published on electrochemotherapy
with bleomycin and cisplatin 11-15
. Overall, the response rate of the treated tumours was approximately 80% objective responses and approximately
70% complete responses 15,16. The effectiveness can be even higher by repetitive treatment 17.
All of these clinical data have enabled electrochemotherapy to be adopted in some European countries as standard treatment, with palliative intent,
on various tumours. The future of this treatment is to introduce electrochemotherapy in treatment of internal tumours and metastases, and in
combined treatment, either with gene therapy or radiation therapy. These attempts are already under way.
Acknowledgements
The authors gratefully acknowledge financial support from the state budget of the Slovenian Research Agency and the European Commission's
ESOPE project (QLK-2002-02003), funded under the 5th Framework Programme. The authors acknowledge the contribution of prof. Marko Snoj,
prof. Maja Cemazar, Matej Merkac and Rado Likon in preparation of this Video-article.
References
1. Mir, L.M. Bases and rationale of the electrochemotherapy. EJC Suppl. 4, 38–44 (2006).
2. Mir, L.M., Gehl, J., Sersa, G., Collins, C.G., Garbay, J.R., Billard, V., Geertsen, P., Rudolf, Z., O’Sullivan, G.C., Marty, M. Standard operating
procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric
pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Suppl. 4, 14–25 (2006).
3. Okino, M., Mohri, H. Effects of high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn. J. Cancer Res. 78,
1319-1321 (1987).
4. Mir, L.M., Banoun, H., Paoletti, C. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct
access to the cytosol. Exp. Cell Res. 175, 15-25 (1988).
5. Sersa, G., Cemazar, M., Miklavcic, D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res.
55, 3450–3455 (1995).
6. Sersa, G., Cemazar, M., Miklavcic, D., Rudolf, Z. Electrochemotherapy of tumours. Radiol. Oncol. 40, 163–174 (2006).
7. Miklavcic, D., Beravs, K., Semrov, D., Cemazar, M., Demsar, F., Sersa, G. The importance of electric field distribution for effective in vivo
electroporation of tissues. Biophys. J. 74, 2152-2158 (1998).
8. Miklavcic, D., Corovic, S., Pucihar, G., Pavselj, N. Importance of tumour coverage by sufficiently high local electric field for effective
electrochemotherapy. EJC Suppl. 4, 45–51 (2006).
9. Sersa, G., Jarm, T., Kotnik, T., Coer, A., Podkrajsek, M., Sentjurc, M., Miklavcic, D., Kadivec, M., Kranjc, S., Secerov, A., Cemazar, M. Vascular
disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Brit. J. Cancer. 98, 388-398 (2008).
10. Mir, L.M., Belehradek, M., Domenge, C., Orlowski, S., Poddevin, B., Belehradek, J. Jr., Schwaab, G., Luboinski, B., Paoletti, C.
Electrochemotherapy, a new antitumor treatment: first clinical trial. C. R. Acad. Sci. III 313, 613–618 (1991).
11. Mir, L.M., Glass, L.F., Sersa, G., Teissie, J., Domenge, C., Miklavcic, D., Jaroszeski, M.J., Orlowski, S., Reintgen, D.S., Rudolf, Z., Belehradek,
M., Gilbert, R., Rols, M.P., Belehradek, J.Jr., Bachaud, J.M., DeConti, R., Stabuc, B., Cemazar, M., Coninx, P., Heller, R. Effective treatment of
cutaneous and subcutaneous malignant tumours by electrochemotherapy. Brit. J. Cancer 77, 2336–2342 (1998).
12. Gothelf, A., Mir, L.M., Gehl, J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation.
Cancer Treat. Rev. 29, 371-387 (2003).
13. Byrne, C.M., Thompson, J.F., Johnston, H., Hersey, P., Quinn, M.J., Hughes, M., McCarthy, W.H. Treatment of metastatic melanoma using
electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res. 15, 45–51 (2005).
14. Sersa, G. The state-of-the-art of electrochemotherapy before the ESOPE study: advantages and clinical uses. EJC Suppl. 4, 52–59 (2006).
15. Sersa, G., Miklavcic, D., Cemazar, M., Rudolf, Z., Pucihar, G., Snoj, M. Electrochemotherapy in treatment of tumours. EJSO 34, 232-240
(2008).
16. Marty, M., Sersa, G., Garbay, J.R., Gehl, J., Collins, C.G., Snoj, M., Billard, V., Geertsen, P.F., Larkin, J.O., Miklavcic, D., Pavlovic, I.,
Paulin-Kosir, S.M., Cemazar, M., Morsli, N., Soden, D.M., Rudolf, Z., Robert, C., O’Sullivan, G.C., Mir, L.M. Electrochemotherapy – an easy, highly
effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of
Electrochemotherapy) study. EJC Suppl. 4, 3–13 (2006).
17. Quaglino, P., Mortera, C., Osella-Abate, S., Barberis, M., Illengo, M., Rissone, M., Savoia, P., Bernengo, M.G. Electrochemotherapy with
intravenous bleomycin in the local treatment of skin melanoma metastases. Ann. Surg. Oncol. 15, 2215-2222 (2008).
Page 2 of 2
Journal of Visualized Experiments www.jove.com
Copyright © 2008 Journal of Visualized Experiments